The British Medical Association has warned the UK Parliament about the government's 'patient choice' initiative, which it believes is worsening health inequalities across the nation, according to PharmaTimes.
New changes occurring in the realm of drug trade, such as Pfizer's move to direct-to-pharmacy distribution in the UK has agitated wholesalers across Europe, according to Scrip World Pharmaceutical News.
Biopure, which develops, manufactures and markets pharmaceuticals called oxygen therapeutics, has reported positive results from its Phase III orthopedic trial.
Telik has announced that the European Patent Office has issued notices of allowance for two applications covering new compounds related to one of Telik's lead clinical candidates, Telintra.
Genmab has announced that it will soon initiate a Phase I/II study to evaluate a subcutaneous route of administration of ofatumumab in rheumatoid arthritis patients, stable on methotrexate.
LifeScan and ResMed have signed an exclusive co-marketing agreement designed to improve the lives of people with type 2 diabetes and sleep-disordered breathing.
DURECT has submitted a new drug application for Remoxy to the FDA. Remoxy, an investigational drug, is a long acting oral formulation of oxycodone intended to treat moderate to severe pain.
Mylan has signed a license and supply agreement with Natco Pharma for its glatiramer acetate pre-filled syringes, a generic version of Teva's Copaxone, which is used to treat multiple sclerosis.
Mylan has announced that the US Court of Appeals for the Federal Circuit has affirmed a May 2007 district court ruling stating that Mylan's 10mg and 20mg Omeprazole delayed-release capsules do not infringe patents asserted against Mylan by AstraZeneca. Omeprazole
Miltenyi Biotec, which develops, produces and sells products for biomedical research and clinical applications, has acquired Switzerland-based Medic Tools.
Sanofi-aventis has announced positive results from a new study that showed Ambien CR CIV tablets 12.5mg provided significant improvement in sleep onset, sleep maintenance and total sleep time over eight weeks in patients with co-morbid insomnia and major depressive disorder
Pfizer and University of California, San Francisco have launched a collaboration that spans many disciplines, several UC campuses and multiple Pfizer research units.
Barr Pharmaceuticals has confirmed that its subsidiary, Barr Laboratories, has initiated a challenge of the patents listed by Tap Pharmaceuticals in connection with its Prevacid SoluTab delayed-release orally disintegrating tablets, 15mg and 30mg.
Pyng Medical has acquired the trauma assets of California-based Bio Cybernetics International, including the Trauma Pelvic Orthotic Device, Mechanical Advantage Tourniquet, and Cricothyrotomy Kit.
Oncolin Therapeutics has signed a sponsored research agreement with The University of Texas MD Anderson Cancer Center in Houston, Texas to support work in the laboratory of Professor Waldemar Priebe.
Syneron Medical has signed a multi-year exclusive provider agreement with Sono Bello Contouring Centers for its LipoLite laser-assisted lipolysis device, and VelaShape cellulite and thigh circumferential reduction device.
IMI Intelligent Medical Implants has appointed Stephen McCormack as its new CEO. Dr McCormack was previously chairman of the board and will remain as a board member.
